| |
|
|
|
|
 상가이름 : 프라그마틱 홈페이지 ┢ 45.ryp383.top ┢ 황금성3게임다운로드 |
|
| 상가주소 : |
|
| 전화번호 : |
|
| 영업시간 : |
|
| 공 휴 일 : |
|
|
기타사항 :
[예약:]
[주차:]
[배달:]
|
|
|
|
| 상 세 소 개 |
【2.ryp383.top】
모바일릴게임사이트야마토게임 방법무료충전 바다이야기모바일게임
슬롯머신 추천 ┢ 54.ryp383.top ┢ 야마토2 릴게임
바다이야기 하는 법 ┢ 11.ryp383.top ┢ 온라인릴게임
릴게임야마토 ┢ 73.ryp383.top ┢ 바다신2다운로드
릴게임꽁머니 ┢ 13.ryp383.top ┢ 씨엔조이 릴게임
릴게임황금성 바다이야기5 우주전함야마토2205 바다이야기5만 프라그마틱 슬롯 사이트 야마토 게임방법 릴게임천국 야마토3게임 다운로드 하기 릴게임 사이트 도메인 오락실게임 파라다이스 PC 릴게임 릴게임바다이야기 무료슬롯 얌얌 오리지날황금성9게임 슬롯 추천 디시 황금성 황금성먹튀 바다이야기 기프트 전환 황금성온라인 프라 그마 틱 무료체험 머니 우주전함 야마토 2199 중고게임기매매 릴게임백경 슬롯머신 사이트 바다이야기 먹튀 황금성게임설명 바둑이라이브 바다이야기 먹튀 돈 받기 오션파다라이스 다운로드 상품권릴게임 릴게임 신천지 야마토다운로드 릴게임강시 야마토2 무료슬롯 얌얌 백경 강원랜드 슬롯머신 확률 공개 블랙잭추천 황금성매장 우주전함 야마토 2199 슬롯릴게임 무료충전바다이야기 바다이야기먹튀 릴게임 코리아 인터넷릴게임 오락실황금성 야마토 창공 알라딘다운로드 온라인 슬롯 배팅법 무료 바다이야기 바다이야기상어 바다이야기 무료체험 온라인오션파라다이스 빠칭코게임다운로드 블랙홀3D 릴게임 인터넷오션파라다이스 동영상황금성 바다이야기 사이트 먹튀 황금성 다운로드 강원랜드 슬롯머신 잭팟 오션파라다이스동영상 릴게임 공략법 프라그마틱 무료체험 야마토 빠칭코 오션파라다이스 다운로드 손오공게임다운 백경게임하는곳주소 황금성게임설명 황금성다운로드 황금성릴 프라그마틱 슬롯 체험 인터넷신천지 온라인 릴게임 신천지예시 야마토 무료 게임 블랙잭하는법 야마토게임 바다이야기 디시 바다 이야기 다운 슬롯머신 추천 다빈치게임 바다이야기게임하는방법 황금성게임다운 릴게임야마토 일본야마토 10원바다이야기 온라인오션게임 바다신게임 바다이야기 디시 바다이야기공략법 손오공릴게임다운로드 무료황금성게임 카지노 잭팟 야마토카지노 올쌈바 릴게임판매 슬롯 잘 터지는 바다이야기온라인 온라인릴게임먹튀검증 야마토게임공략방법 슬롯머신 이기는 방법 알라딘릴게임 사이트 인터넷빠찡꼬 모바일릴게임 종류 야마토게임동영상 황금성갈가리 온라인백경 꽁머니 야마토2게임하기 오리지날릴게임 오션파라다이스예시 황금성갈갈이 황금성pc버전 슬롯머신 잭팟 체리마스터 다운로드 바다이야기예시종료 모바일신천지모바일 바다이야기게임방법 야마토2 pc버전 인터넷야마토게임 야마토게임무료다운받기 야마토게임다운 황금성 오징어릴게임 손오공릴게임다운로드 This article was released as Pharm Edaily Premium Content on May 27, 2025, at 7:35 AM.
[Shin-Min Joon, Edaily Reporter] On May 26 the Korean pharmaceutical and biotech market saw sharp rallies in the share prices of Raphas, Daewhapharmand Cellumed. Raphas surged on news of progress in its microneedle based obesity patch. Daewhapharm gained after announcing that Pha원유관련주식
se 3 clinical trial results for its oral cancer drug Liporaxel were selected for presentation at a major global oncology congress. Cellumed’s rally was driven by expectations of improved earnings from엔터테인먼트주식
strong sales of its dental bone graft products. ·
Raphas stock trend on May 26. (Image=MP Doctor)
Raphas So2011주식시장
ars on Obesity Patch Clinical Results
According to MP DOCTOR (formerly MarketPoint) by KG Zeroin Raphas shares jumped 29.75% to close at won 21,150, hitting the upper trading limiWRAP
t early in the session. Raphas, in partnership with Daewon Pharmaceutical, is developing DW1022, a microneedle patch version of semaglutide, the active ingredient in blockbuster obesity drug Wegovy. T단타
his marks the world’s first attempt to develop an obesity treatment patch using microneedle technology.
Raphas completed a Phase 1 clinical trial of DW1022 at the end of last year. The results showed a bioavailability approximately 30% higher than that of subcutaneous injections. Considering that the oral semaglutide (Rybelsus by Novo Nordisk) has a bioavailability of less than 0.5% compared to subcutaneous injections, DW1022 achieves nearly 60 times greater absorption efficiency.
The Phase 1 study also confirmed the drug’s pharmacokinetics tolerability and safety after a single daily application. Raphas plans to conduct further trials to evaluate repeated dose weight loss efficacy and pharmacokinetics at higher concentrations. The company is also exploring a once weekly formulation that could maintain efficacy with weekly application. To date, no microneedle based prescription drug has been commercialized globally.
Beyond the obesity patch Raphas is developing other microneedle based products. The company recently launched Reti-RN, the world’s first patch combining retinol and polydeoxyribonucleotide (PDRN) in a stable formulation. Retinol is known for its anti-aging effects, while PDRN, extracted from salmon DNA, promotes skin regeneration and elasticity. Raphas is also working on a hepatitis B vaccine patch using microneedle technology.
A Raphas spokesperson commented “Our microneedle based obesity patch development is progressing smoothly and we are committed to ensuring its timely development.”
DaewhapharmRises on Global Cancer Conference Presentation
Daewhapharmshares climbed 9.96% to won 15,020, buoyed by the news that its Liporaxel data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, one of the world’s three largest oncology conferences, scheduled from May 30 to June 3 in Chicago.
Liporaxel is an oral formulation and improved version of Taxol (paclitaxel), a blockbuster intravenous anticancer drug developed by Bristol Myers Squibb that has been in use for over 30 years. Daewhapharmis expanding Liporaxel’s indications from gastric cancer to recurrent and metastatic breast cancer.
In results received earlier this year from a contract research organization (CRO), Liporaxel demonstrated non-inferior efficacy and safety compared to IV paclitaxel in a multinational Phase 2/3 trial involving 582 patients (33 in Phase 2 and 549 in Phase 3). The Phase 2 trial was conducted at 12 sites in Korea, and the Phase 3 trial at 51 sites across Korea, China, Hungary, Serbia, and Bulgaria.
For the primary endpoint of progression free survival (PFS) in the per-protocol set (PPS), Liporaxel achieved a median PFS of 10.02 months, compared to 8.54 months for the IV formulation. Secondary endpoints such as overall survival (OS), objective response rate (ORR), and disease control rate (DCR) also showed trends of non inferiority.
In terms of safety, the incidence rates of treatment emergent adverse events (TEAEs) and adverse drug reactions (ADRs) were comparable between the oral and injectable forms. Liporaxel is currently being marketed in China through local partner Haihe Biopharma and distributor 3S BIO. Daewhapharmalso plans to expand into the transdermal drug delivery system (TDDS) market with products such as dermal fillers and dementia patches.
A company representative noted “News of our abstract selection at ASCO appears to have positively influenced our stock performance.”
Cellumed Advances on Strong Sales of Dental Bone Graft
Cellumed shares rose 10.33% to won 961, driven by strong sales of its Rafugen Dental graft, a high performance bone graft product used in dental implants to restore bone defects.
Cellumed recently doubled its production capacity through process improvements and expanded its global raw material supply chain to ensure a stable manufacturing system. This enables the company to respond quickly to growing demand.
The growth of the Korean dental implant market supports this trend. According to data from the Health Insurance Review and Assessment Service, the number of dental implant patients rose from 719,309 in 2020 to 837,634 in 2023 a 16% increase reflecting the aging population and heightened awareness of oral health.
In 2024 Cellumed posted won 129.1 billion in revenue up 35% year on year and narrowed its operating loss to won 6.8 billion from won 10.5 billion. The company is actively strengthening its global raw material supply through partnerships with overseas firms to ensure stable production of its core bone regeneration and skin graft products.
A company official stated “Demand for Rafugen Dental is surging in clinical settings, particularly in the Seoul metropolitan area. The product has received favorable reviews, and we continue to receive requests for increased supply.”
The spokesperson added “Cellumed is aggressively marketing to make the dental sector a core business. We aim to expand our market share through stable supply, technological strength, and the launch of new high-efficacy products.”
신민준 (adonis@edaily.co.kr)
|
|
